In vitro evaluation of hepatic and extra-hepatic metabolism of coumarins using rat subcellular fractions: Correlation of in vitro clearance with in vivo data

Drug Metabolism and Drug Interactions

Volumn 23, Issue 3-4, 2008, Pages 329-351

  Behera, Dayanidhi ^a   Damre, Anagha ^b   Varghese, Alice ^b   Addepalli, Veeranjaneyulu ^a  

^a NMIMS UNIVERSITY   (India)

^b Piramal Enterprises Limited   (India)

Author keywords

7 ethoxycoumarin; 7 hydroxycoumarin; Cytochrome P450; Intrinsic clearance; Organ clearance; Scaling

Indexed keywords

7 ETHOXYCOUMARIN; COUMARIN DERIVATIVE; UMBELLIFERONE; 7-ETHOXYCOUMARIN; 7-HYDROXYCOUMARIN; ANTICOAGULANT AGENT; UMBELLIFERONE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BRAIN MICROSOME; BRAIN TISSUE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG METABOLISM; IN VITRO STUDY; INTESTINE MUCOSA; KIDNEY MICROSOME; KIDNEY PARENCHYMA; LIVER METABOLISM; LIVER MICROSOME; LIVER PARENCHYMA; LUNG PARENCHYMA; MALE; NONHUMAN; PREDICTION; RAT; TISSUE SPECIFICITY; ANIMAL; CELL CULTURE; CELL FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; PROCEDURES; REPRODUCIBILITY; WISTAR RAT;

ANIMALS; ANTICOAGULANTS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SUBCELLULAR FRACTIONS; UMBELLIFERONES;

EID: 60749089165     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2008.23.3-4.329     Document Type: Article

References (34)

1. Yan Z, Caldwell GW. Metabolism profiling and cytochrome P450 inhibition and induction in drug discovery. Curr Top Med Chem 2001; 1: 403-425.
2. Nassar A-EF, Kamel AM, Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov Today 2004; 9: 1020-1028.
3. De Graaf IAM, de Kanter R, De Jager MH, et al. Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 2006; 34: 591-599.
4. Griffin SJ, Houston JB. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab Dispos 2005; 33: 115-120.
5. Shimada T, Tsumura F, Yamazaki H. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 1999; 27: 1274-1280.
6. Skett P, Tyson C, Guillouzo A, Maier P. Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem Pharmacol 1995; 50: 280-285.
7. Blaauboer BJ, Boobis AR, Castell JV, et al. The practical applicability of hepatocyte cultures in routine testing: the report and recommendations of ECVAM Workshop 1. ATLA 1994; 22: 231-241.
8. Bach PH, Vickers AEM, Fisher R, et al. The use of tissue slices for pharmacotoxicology studies: the report and recommendations of ECVAM Workshop 20. Altern Lab Anim 1996; 24: 893-923.
9. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290: 160-166.
10. Greenlee WF, Poland A. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachloro-dibenzo-p-dioxin. J Pharmacol Exp Ther 1978; 205: 596-605.
11. Ryan DE, Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 1990; 45: 153-239.
12. Lake BG. Coumarin metabolism, toxicity and carcinogenecity: relevance for human risk assessment. Food Chem Toxicol 1999; 37: 423-453.
13. Boobis AR, Whyte C, Davies SD. Selective induction and inhibition of the components of 7-ethoxycoumarin O-deethylase in the rat. Xenobiotica 1986; 16: 233-238.
14. Rogiers V, Adriaenssens L, Vandenberghe Y, Gepts E, Callaerts A, Vercruysse A. Critical evaluation of 7-ethoxycoumarin O-deethylase activity measurement in intact rat hepatocytes. Xenobiotica 1986; 16: 1701-1706.
15. Fry JR, Garle MJ, Lal K. Differentiation of cytochrome P-450 inducers on the basis of 7-alkoxycoumarin O-deethylase activities. Xenobiotica 1992; 22: 211-215.
16. Bayliss MK, Bell JA, Wilson K, Park GR. 7-Ethoxycoumarin O-deethylase kinetics in isolated rat, dog, and human hepatocytes. Xenobiotica 1994; 24: 231-241.
17. Worboys PD, Bradbury A, Houston JB, Kinetics of drug metabolism in rat liver slices: rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. Drug Metab Dispos 1995; 23: 393-397.
18. Ball SE, Thiel VE, Tio CO, et al. 7-Ethoxycoumarin metabolism by precision-cut rat hepatic slices. Drug Metab Dispos 1996; 24: 383-389.
19. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes 1. Evidence for its hemoprotein nature. J Biol Chem 1964; 239: 2370-2378.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
21. Iyer KR, Sinz MW. Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations. Chem Biol Interact 1999; 118: 151-169.
22. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrates and inhibitor probes for human cytochromes. J Pharmacol Exp Ther 1993; 265: 401-407.
23. Lavhekar SS, Bhopale AK, Lohade AA, Coutinho EC, Iyer KR. Determination of microsomal CYP2A6 activity by high performance liquid chromatography. Indian J Pharm Sci 2007; 69: 448-451.
24. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
25. De Kanter R, Monshouwer M, Draaisma AL, et al. Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon. Xenobiotica 2004; 34: 229-241.
26. Trudeau-Lame ME, Kalgutkar AS, LaFontaine M. Pharmacokinetics and metabolism of the reactive oxygen scavenger α-phenyl-N-tert-butylnitrone in the male Sprague-Dawley rat. Drug Metab Dispos 2003; 31: 147-152.
27. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
28. Nakai M, Sasaki M, Okubo S, Yoshioka T, Kunieda T. Intrapulmonary bronchial blood flow of rats as studied by the microsphere method. Heart Vessels 1991; 6: 84-89.
29. Carlile DJ, Stevens AJ, Ashforth EI, Waghela D, Houston JB. in vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Use of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. Drug Metab Dispos 1998; 26: 216-221.
30. Ritschel WA, Johnson RD, Vachharajani NN, Hussain AS. Prediction of the volume of distribution of 7-hydroxycoumarin in man from in vitro and ex vivo data obtained in rat. Biopharm Drug Dispos 1992; 13: 389-402.
31. Yamazaki H, Inoue K, Mimura M, Oda Y, Guengerich FP, Shimida T. 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 1996; 51: 313-319.
32. Honkakoski P, Negishi M. The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab Dispos 1997; 29: 977-996.
33. Jung B, Graf H, Ullrich V. A new monooxygenase product from 7-ethoxycoumarin and its relation to the O-deethylation reaction. Biol Chem Hoppe-Seyler 1985; 366: 23-31.
34. Cohen AJ. Critical review of the toxicology of coumarin with special references to interspecies differences in metabolism and hepatotoxic response and their significance to man. Food Chem Toxicol 1979; 17: 277-289.